期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

解偶联蛋白2在乳腺癌组织及耐药细胞中的表达 被引量：1

Expression of mitochondrial UCP2 in human breast cancer tissue and drug-resistant cancer cell
原文传递
导出
摘要 目的探讨乳腺癌组织和耐药细胞中解偶联蛋白2(UCP2)的表达。方法免疫组织化学方法检测UCP2在乳腺癌和癌旁正常组织中的表达,Western blot检查乳腺癌细胞MCF-7和紫杉醇耐药细胞MX-1/T中UCP2的表达。结果 UCP2在乳腺癌组织中的表达量明显高于癌旁正常组织,并且紫杉醇耐药的乳腺癌细胞MX-1/T中UCP2的表达亦显著高于乳腺癌细胞MCF-7(P<0.05)。结论 UCP2在乳腺癌组织和紫杉醇耐药乳腺癌细胞中均高表达。 Objective To explore the expression of uncoupling protein 2 （UCP2） in breast cancer tissue and drug-resistant cancer cells. Methods The expressions of UCP2 in breast cancer and tumor-adjacent tissues were detected by immunohistoehemistry. The expressions of UCP2 in breast cancer cell MCF-7 and taxobresistant cell MX-1/T were detected by Western blot. Results The expression of UCP2 in breast cancer was more than that in tumor-adjacent tissues,which was more in taxol-resistant cell MX-1/T than that in breast cancer＇cell MCF-7 （P（0. 05）. Conclusion UCP2 is of erexpressed in human breast cancer and drug-resistant breast cancer cell.
作者 孙岩 袁渊 张莉莉 朱虹 胡赛男
机构地区 江苏省肿瘤医院内科
出处 《江苏医药》 CAS 北大核心 2014年第3期277-279,F0003,共4页 Jiangsu Medical Journal
基金 江苏省卫生厅面上项目(Z201006)
关键词 解偶联蛋白2 乳腺癌 耐药 Uncoupling protein 2 Breast cancer Drug-resistance
分类号 R737 [医药卫生—肿瘤]
  • 相关文献

参考文献8

  • 1Finkel T,Holbrook NJ. Oxidants,oxidative stress and the biology of ageing[J].{H}NATURE,2000,(6809):239247.
  • 2Benhar M,Engelberg D,Levitzki A. ROS,stress-activated kinases and stress signaling in cancer[J].{H}EMBO Reports,2002,(5):420-425.
  • 3Kim HS,Park KG,Koo TB. The modulating effects of the overexpressionof uncoupling protein 2 on the formation of reactive oxygen speciesin vascular cells[J].{H}Diabetes Research and Clinical Practice,2007,(Suppl 1):S46-S48.
  • 4Fatehi-Hassanabad Z,Chan CB. Expression of PPARalpha modifies fattyacid effects on insulin secretion in uncoupling protein-2 knockout mice[J].Nutr Metab(Lond),2007.6.
  • 5Horimoto M,Resnick MB,Konkin TA. Expression of uncoupling protein-2 in human colon cancer[J].{H}Clinical Cancer Research,2004,(18 Pt 1):6203-6207.
  • 6Cuezva JM,Krajewska M,de Heredia ML. The bioenergetics signature of cancer:a marker of tumor progression[J].{H}CANCER RESEARCH,2002,(22):6674-6681.
  • 7Simoneau JA,Kelley DE,Warden C. Obesity and increased contractile activity influence the protein content of UCP2 in human skeletal muscle[J].{H}International Journal of Obesity and Related Metabolic Disorders,1999,(Suppl 6):S68-S71.
  • 8张在永,戴纪刚,闵家新,蒋力.解偶联蛋白2和缺氧诱导因子1α在肺癌组织中的表达[J].中国药业,2012,21(9):5-8. 被引量：3

二级参考文献12

  • 1Warburg O. On the origin of cancer cells[J]. Science, 1956, 123(3 191 ): 309 - 314.
  • 2Brand MD, Affourtit C, Esteves TC, et al. Mitochondrial superoxide: production,biological effects, and activation of uncoupling proteins[J]. Free Radic Biol Med,2004, 37:755 -767.
  • 3Simoneau JA,Kelley DE,Warden C. Obesity and increased contractile activity influence the protein content of UCP2 in human skeletal muscle [ J ]. Int J Obes Relat Metab Disord, 1999,23 (Suppl 6): S68 - S71.
  • 4Berthiaume E,Derdak Z,Konkin TA, et al. Increased expression of uncoupling protein- 2 in cholangioearcinoma cells may confer resistance to apoptosis[J]. Hepatology,2004,40: 372a - 373a.
  • 5Pouyssegur J,Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression[J]. Nature,2006,441(7 092): 437 - 443.
  • 6Horimoto M, Resnick MB,Konkin TA, et al. Expression of uncoupling protein- 2 in human colon cancer [J]. Clin Cancer Res,2004,10: 6 203 - 6 207.
  • 7Finkel T, Holbrook NJ. Oxidants,oxidative stress and the biology of ageing[J]. Nature,2000,408 (6 809:239 -247.
  • 8Zhong H, De Marzo AM, Laughner E, et al. Overexpression of bypoxia-inducible factor lalpha in common human cancers and their metastases[J]. Cancer Res, 1999,59: 5 830 - 5 835.
  • 9Baffy G. Uncoupling protein -2 and cancer[J]. Mitochondrion, 2010, 10:243 - 252.
  • 10Ristow M. Oxidative metabolism in cancer growth[J]. Curr Opin Clin Nutr Metab Care,2006,9:339 - 345.

共引文献2

同被引文献16

  • 1Hofman J, Skarka A, Havrankova J, et al. Pharmacokinetic interactions of breast cancer chemotherapeutics with human doxorubicin reductases [J]. Biochem Pharmacol, 2015, 96(3) 168-178.
  • 2Kim KY, Kim SH, Yu SN, et al. Salinomycin enhances doxo- rubicin induced cytotoxicity in multidrug resistant MCF-7/ MDR human breast cancer cells via decreased efflux of doxoru- bicin [J]. Mol MedRep, 2015, 12(2) :1898-1904.
  • 3Lv J, Xia K, Xu P, et al. miRNA expression patterns in che- moresistant breast cancer tissues [J]. Biomed Pharmacother, 2014, 68(8) :935-942.
  • 4Achari C, Winslow S, Ceder Y, et al. Expression of miR-34c induces G2/M cell cycle arrest in breast cancer ceils [ [J]. BMC Cancer, 2014, 26(14): 538.
  • 5Navarro F, Lieberman J. miR-34 and p53: New Insights into a Complex Functional Relationship [J]. PLoS One, 2015, 10 (7) :e0132767.
  • 6Xiang S, Dauchy RT, Hauch A, et al. Doxorubicin resistance in breast cancer is driven by light at night induced disruption of the circadian melatonin signal [J]. J Pineal Res, 2015, 59 (1) 60-69.
  • 7Gezer U, Keskin S, I ci A, et al. Abundant circulating mi- croRNAs in breast cancer patients fluctuate considerably during neoadjuvant chemotherapy[J]. Oncol Lett, 2014, 8 (2) : 845- 848.
  • 8Medimegh I, Omrane I, Privat M, et al. MicroRNAs expres-sion in triple negative vs non triple negative breast cancer in Tunisia.. interaction with clinical outcome [J]. PLoS One, 2014, 9(11):e111877.
  • 9Li R, Shi X, Ling F, et al. MiR 34a suppresses ovarian cancer proliferation and motility by targeting AXL[J]. Tumour Biol, 2015, 36(9):7277- 7283.
  • 10Stahlhut C, Slack FJ. Combinatorial Action of MicroRNAs let- 7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation[J]. Cell Cycle, 2015, 14(13) :2171-2180.

引证文献1

二级引证文献2

江苏医药
2014年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部